Literature DB >> 24154628

Base excision repair AP endonucleases and mismatch repair act together to induce checkpoint-mediated autophagy.

Tanima SenGupta1, Maria Lyngaas Torgersen, Henok Kassahun, Tibor Vellai, Anne Simonsen, Hilde Nilsen.   

Abstract

Cellular responses to DNA damage involve distinct DNA repair pathways, such as mismatch repair (MMR) and base excision repair (BER). Using Caenorhabditis elegans as a model system, we present genetic and molecular evidence of a mechanistic link between processing of DNA damage and activation of autophagy. Here we show that the BER AP endonucleases APN-1 and EXO-3 function in the same pathway as MMR, to elicit DNA-directed toxicity in response to 5-fluorouracil, a mainstay of systemic adjuvant treatment of solid cancers. Immunohistochemical analyses suggest that EXO-3 generates the DNA nicks required for MMR activation. Processing of DNA damage via this pathway, in which both BER and MMR enzymes are required, leads to induction of autophagy in C. elegans and human cells. Hence, our data show that MMR- and AP endonuclease-dependent processing of 5-fluorouracil-induced DNA damage leads to checkpoint activation and induction of autophagy, whose hyperactivation contributes to cell death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24154628      PMCID: PMC3826653          DOI: 10.1038/ncomms3674

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


5-Fluorouracil (5-FU) remains a central component of systemic treatment of a wide range of solid cancers in the adjuvant setting1. The active metabolite, 5-fluoro-2′-deoxyuridine monophosphate, inhibits thymidylate synthase, which leads to imbalanced nucleotide pools with subsequent incorporation of dUTP and 5-fluoro-2′-dUTP into DNA, and the corresponding ribonucleotides into RNA2. As the resulting uracil and fluorouracil (FUra) bases in DNA do not lead to formation of strand breaks directly, it is thought that repair intermediates generated through incomplete or aberrant processing of the original lesions by DNA repair enzymes is the basis for DNA-directed toxicity1. Uracil and FUra in DNA are primarily repaired via the base excision repair (BER) pathway3. BER is initiated by a uracil–DNA glycosylase (UDG), which excises the damage as a free base. The resulting abasic (apurinic/apyrimidinic (AP)) site is incised by an AP endonuclease to generate a single-strand break, and further processing leads to replacement of one or two nucleotides. All five mammalian UDGs may process uracil or FUra (for review see ref. 4), but conflicting reports exists as to whether they mediate DNA-directed toxicity2567. Furthermore, no good correlation between BER deficiency and therapeutic response has been observed in clinical material4. In contrast, the DNA mismatch repair (MMR) pathway is an important determinant for 5-FU toxicity, and MMR deficiency is associated with resistance to 5-FU (ref. 1). In the MMR pathway, the MutS complex (MSH-2/MSH-6) binds DNA damage in a mismatch context8 and recruits the MutL complex (MLH-1/PMS-2). The MutS/MutL complex then travels away from the mismatch to search for a nick, which is required for loading of an exonuclease (EXO-1) that removes the lesion together with an extended stretch of the surrounding DNA. Thus, processing of DNA damage through the MMR pathway leads to the generation of long stretches of single-stranded DNA, which will be coated by replication protein A (RPA) before replicative polymerases are recruited to fill in the gap9. The mechanistic basis for involvement of MMR in response to 5-FU is puzzling, as 5-FU primarily leads to incorporation of uracil and FUra opposite adenine to generate BER substrates. The high degree of redundancy among UDGs effectively prevents further clarification of the division of labour between BER and MMR in activation of DNA-directed toxicity in human cells. Thus, we used Caenorhabditis elegans as a model to investigate the function of the two DNA repair pathways in eliciting 5-FU toxicity. C. elegans has only one characterized UDG, the enzyme UNG-1 (ref. 10), and has significantly contributed to our understanding of the role of DNA repair pathways in initiating DNA damage response (DDR) signalling in response to misincorporated uracil11. Furthermore, as C. elegans also has only one MutS complex, it allows genetic interrogation of the separate role of BER and MMR in eliciting DNA-mediated toxicity in response to 5-FU. Here we show that the DNA damage recognition complex of MMR, but not BER, acts as a sensor of DNA damage induced by 5-FU. Furthermore, epistasis analyses show that the BER AP endonucleases APN-1 and EXO-3 function in the same pathway as MMR to induce toxicity in response to 5-FU. Immunohistochemical analyses suggest that EXO-3 generates DNA nicks required for MMR activation, whereas APN-1 is required for checkpoint activation. Processing of DNA damage via this pathway, in which both BER and MMR enzymes are required, leads to induction of autophagy in C. elegans and in human U2OS cells. This suggests that failure to process 5-FU-induced DNA damage via this pathway is a basis for resistance.

Results

C. elegans MMR and BER mutants are resistant to 5-FU

Removal of uracil or FUra bases from DNA is generally believed to be required for generating the repair intermediates leading to DNA-directed toxicity induced by 5-FU. Thus, we asked whether mutants of the lesion recognition enzymes in the BER or MMR (Fig. 1a) pathways led to 5-FU resistance in C. elegans.
Figure 1

Epistatic interactions between MutS and the BER AP endonucleases with respect to 5-FU sensitivity.

(a) Cartoons showing schemes of the (i) BER and (ii) MMR pathways. F1 survival (b) in N2 wild type (black diamonds) and ung-1 mutants (red squares), (c) following the depletion of EXO-3 (red triangles), APN-1 (blue circles) or control RNAi (L4440, black diamonds) in the N2 wild-type background, and (d) in msh-2(ok2410) (orange triangles), msh-6(pk2504) (green circles) and mlh-1(ok1917) (grey squares) mutants. (e) Western blottings showing expression of MSH-6 protein in the wild type strain grown on E. coli expressing control (N2) or the indicated RNAi, as well as in msh-6(pk2504) and msh-2(ok2410) mutants (top panel), and expression of MSH-2::GFP fusion protein in transgenic worms grown on E. coli expressing RNAi for MSH-2, MSH-6 or empty vector control as indicated (lower panel). Actin was used as the loading control. (f) F1 survival after depletion of MSH-2 and MSH-6 in the mlh-1(ok1917) mutant. (g,h) F1 survival after depletion of the AP endonucleases EXO-3 and APN-1 in (g) the msh-6(pk2504) or (h) msh-2(ok2410) mutant background. Kruskal–Wallis one-way analysis on ranks (P=0.963 and P=0.985 in h and g, respectively). Mann–Whitney rank-sum test failed to identify a difference in median survival after depleting EXO-3 in the msh-6 mutant (g, P=0.929). (i) F1 survival following depletion of the indicated genes in exo-3(tm4374) mutants. (j) F1 survival in msh-6(pk2504), exo-3(tm4374) and exo-3;msh-6 double mutants. (k) F1 survival in exo-3(tm4374), mlh-1(ok1917) and exo-3;mlh-1 double mutants. All survival curves (b–d,f–k) show the mean±s.d. for each data point from three independent experiments.

A null mutant of the UNG-1 enzyme, ung-1(qa7600; ref. 11, also see Supplementary Fig. S1 for description of the mutant alleles) was as sensitive to 5-FU as the wild type (N2; Fig. 1b). In contrast, pronounced 5-FU resistance was observed after RNA interference (RNAi)-mediated depletion of the AP endonucleases EXO-3 and APN-1 (Fig. 1c). As the AP endonucleases act downstream of UNG-1 in the BER pathway (Fig. 1a), this surprising result indicates that DNA-mediated toxicity proceeds via an UNG-1-independent alternative pathway that also requires AP endonucleases. An MSH-6 mutant, msh-6(pk2504) was remarkably resistant to 5-FU (Fig. 1d). After treating nematodes with 2 μM 5-FU, >80% of the msh-6(pk2504) mutant offspring developed into adults compared with <5% of the wild type (Fig. 1d). In contrast, only 50% of MSH-2 mutants, msh-2(ok2410), developed into adults (Fig. 1d) and mlh-1(ok1917) mutant animals were as sensitive as msh-2(ok2410) mutants (Fig. 1d). This surprising intermediate phenotype of msh-2(ok2410) mutants would be consistent with aberrant processing of 5-FU-induced DNA damage initiated by MSH-6 without appropriate recruitment of downstream repair factors. This was unexpected given that MSH-2 acts together with MSH-6 in the MutS complex and the stability of human MSH-6 depends on MSH-2 (ref. 12). However, western blot analysis confirmed that in C. elegans, MSH-6 was expressed in msh-2(ok2410) mutants and in the wild type after RNAi-mediated depletion of MSH-2, but was not detected in msh-6(pk2504) mutants and msh-6(RNAi) animals (Fig. 1e). Moreover, expression of an MSH-2::GFP translational fusion protein could be detected after depleting MSH-6 but not MSH-2 (Fig. 1e). As depletion of MSH-6 or MSH-2 was epistatic to the mlh-1(ok1917) mutation (Fig. 1f), we conclude that processing of 5-FU-induced DNA damage through the MMR pathway is the basis for DNA-directed toxicity, and that MSH-6 seems to have an upstream function in lesion processing (see Supplementary Fig. S2 for RNAi efficiency and confirmation that phenotypes induced by RNAi resemble mutant phenotypes). To test whether the AP endonucleases act in the same pathway as MMR to mediate 5-FU-directed toxicity, we depleted APN-1 and EXO-3 in msh-6 and msh-2 mutant animals (Fig. 1g,h, respectively). In both cases epistasis was observed, as no statistically significant difference in median survival was found between the groups. Thus, the BER AP endonucleases act in the same pathway as MMR to mediate 5-FU toxicity. Further epistasis analyses in exo-3(tm4374) mutants suggested that MSH-6 operates upstream of EXO-3, whereas MSH-2, MLH-1 and APN-1 probably act downstream of EXO-3, as their depletion resulted in 5-FU sensitivity indistinguishable from the exo-3(tm4374) mutant-fed control RNAi (Fig. 1i). Analyses in exo-3;msh-6 and exo-3;mlh-1 double mutants (Fig. 1j,k, respectively) confirmed the epistasis between EXO-3, and both MSH-6 and MLH-1. Finally, the msh-6 single and exo-3;msh-6 double mutants showed most pronounced tolerance to 5-FU, supporting an upstream role of MSH-6 in eliciting 5-FU toxicity. Hence, the epistasis experiments support a model where the BER AP endonucleases function downstream of MutS to elicit DNA-directed toxicity in response to 5-FU.

DNA repair-dependent checkpoint activation

Next, we asked whether the processing of 5-FU-induced DNA damage led to apoptosis. Despite the appearance of cytological markers for DDR activation (Supplementary Fig. S3a,b), apoptotic cell death was not observed upon 5-FU treatment neither in the germline (Supplementary Fig. S3c)13 nor in embryos (Supplementary Fig. S3d). However, RPA-1-positive foci, which are early markers for DDR activation, accumulated in 5-FU-treated embryos (Fig. 2a). RPA-1 foci were observed in animals depleted for UNG-1 (Fig. 2b). In contrast, RPA-1 focus formation depended on MSH-6 (Fig. 2a,b and Supplementary Table S1) and, on further processing, through the MMR pathway, as RPA-1 foci did not form in the mlh-1(ok1917) mutant and were suppressed in the exo-1(tm1842) mutant (Fig. 2c and Supplementary Table S2). Hence, we conclude that RPA-1 focus formation depends on processing 5-FU-induced DNA damage through the MMR pathway.
Figure 2

DNA damage checkpoint activation in C. elegans.

(a) Immunofluorescence images showing anti-RPA-1-positive foci in response to 5-FU after depleting the indicated genes by RNAi or empty vector control RNAi (L4440; scale bars, 5 μm). (b) Quantification of the fraction (%) of 5-FU-treated embryos that contain RPA-1-positive foci. (c) Quantification of the fraction (%) of 5-FU-treated embryos that contain RPA-1-positive foci in N2, mlh-1(ok1917) and exo-1(tm1842) mutants fed control (L4440) or RNAi targeting APN-1 (apn-1). (d) Immunofluorescence showing CHK-1 phosphorylation at Ser139 in response to 5-FU in N2 but not in msh-6(pk2504) mutants or in N2 after apn-1(RNAi) (scale bars, 5 μm). (e) Quantification of the fraction (%) of 5-FU-treated embryos with phospho-CHK-1 foci. (f) Western blottings showing H1X.101 levels in N2 and msh-6 mutants, treated (+) or not (−) with 5-FU. Actin was used as loading control. (g) Quantification of H1X.101 levels relative to actin in control versus 5-FU-treated worms. (b,c,e,g) Bar graphs show the mean±s.d. from three independent experiments.

The epistasis of MSH-6 between EXO-3 and APN-1 (Fig. 1g,j) could be explained if these endonucleases provide the DNA nicks required for the loading of EXO-1. If so, we would expect that depletion of the BER AP endonucleases prevented RPA-1 focus formation. This was indeed the case for EXO-3 (Fig. 2b and Supplementary Table S1). In contrast, depletion of APN-1, which, according to our epistasis analysis, acts downstream of EXO-3, did not significantly suppress RPA-1 focus formation in the wild-type background (Fig. 2a,b). However, depletion of APN-1 in exo-1(tm1842) mutants completely abrogated RPA-1 focus formation (Fig. 2c and Supplementary Table S2). The different outcomes with respect to RPA-1 focus formation confirmed that APN-1 and EXO-3 have non-redundant functions. The finding that EXO-3 was required for RPA-1 filament formation suggested that it might contribute to generate nicks required for the activation of MMR. RPA-1 filament formation in response to DNA damage is an indication of DNA damage checkpoint activation that, in 5-FU-treated human cells, involves CHK-1 phosphorylation14. 5-FU induced-phosphorylation of CHK-1 in wild-type C. elegans but not in msh-6(pk2504) mutant embryos (Fig. 2d,e). Interestingly, CHK-1 phosphorylation was not induced in APN-1-depleted embryos (Fig. 2d,e) despite the presence of RPA-1 foci. The immunohistochemical analysis therefore supports that checkpoint activation depends on DNA repair. Although MSH-6 function is required both for RPA-1 focus formation and CHK-1 phosphorylation, APN-1 is dispensable for RPA-1 filament formation. The absence of RAD-51-positive foci (Supplementary Table S3) showed that checkpoint activation was not likely to be a result of DNA double-stranded break (DSB) formation. However, compared with untreated nuclei, 5-FU-treated nuclei were larger with faint DAPI (4′,6-diamidino-2-phenylindole) staining already at the four- to six-cell stage embryo (Fig. 2a). Taken together, this suggested that 5-FU primarily leads to chromatin decompaction rather than DSB formation. Consistently, the maximum nuclear diameter, defined by the perimeter of lamin-1 (LMN-1) staining in the four-cell stage embryo, increased from 8.2 to 9.0 μm (Student’s t-test, P<0.05) by 5-FU treatment concomitant with reduced DAPI staining intensity in an MSH-6-dependent manner (Supplementary Fig. S4). Chromatin decompaction was confirmed by the loss of linker histone H1X in 5-FU-treated embryos (Fig. 2f,g). H1X levels were not reduced upon 5-FU treatment in the msh-6(pk2504) mutant. This gives independent confirmation that chromatin decompaction and checkpoint activation depended on DNA-repair-mediated processing of 5-FU-induced DNA damage.

5-FU induces autophagy in C. elegans

As we recently showed that uracil incorporation induces cell death with both apoptotic and autophagic features15, we tested whether 5-FU may induce autophagy as an alternative cell death response16. During the process of macroautophagy (hereafter, it is referred to as autophagy), parts of the cytoplasm are sequestered by a double lipid layer that grows to form a small vesicle (autophagosome). The autophagosome then fuses with a lysosome to generate an autolysosome, in which the cargo is degraded by acidic hydrolases. To monitor the activation of autophagy, we used the transgenic reporter strain expressing LGG-1 (C. elegans Atg8/LC3) in fusion with green fluorescent protein (GFP). LGG-1 remains associated with autophagic membranes from the early nucleation step until fusion with lysosomes. Increased LGG-1 expression and appearance of GFP::LGG-1-positive puncta indicated that autophagy was activated in the embryos of 5-FU-treated hermaphrodites (Fig. 3a). LGG-1 accumulation was dependent on the core autophagic machinery, as it was suppressed after depletion of UNC-51 (C. elegans ULK1/Atg1 homologue), a serine/threonine kinase that regulates autophagy induction; the class III phosphatidylinositol 3-kinase (PI3K) complex subunit BEC-1 (C. elegans beclin1/Atg6), which is required for vesicle nucleation; and ATG-7, an E1-like enzyme involved in conjugation of the ubiquitin-like proteins LGG-1 and ATG-12 to autophagic membranes (Fig. 3a). Depletion of LGG-1 itself suppressed puncta formation in a BEC-1::GFP reporter strain (Supplementary Fig. S5a–c). To exclude the possibility that 5-FU-induced autophagy could be an artefact of the transgenic reporter system used, we monitored the expression of the endogenous VPS-34 protein (a homologue of human class III PI3K) that interacts with BEC-1 (17). Confirming autophagy activation in response to 5-FU treatment, an overall increase in VPS-34 expression was observed together with the appearance of VPS-34-positive puncta around the nuclear periphery and in the cytoplasm (Fig. 3b). Distinct VPS-34 foci were also observed in the nucleoli, indicating that VPS-34 shuttles between the nucleus and cytoplasm, similar to what was previously described for its interaction partner Beclin 1 (ref. 18). Furthermore, as LGG-1 itself is degraded as part of the autophagic process, the appearance of a 25-kDa band corresponding to GFP in 5-FU-treated embryos, which disappeared upon addition of the PI3K inhibitor 3-methyladenine (3-MA), confirmed increased autophagic flux upon 5-FU treatment (Fig. 3c). Although autophagy primarily acts as a prosurvival mechanism following various forms of stress, including starvation, excessive activation of autophagy can promote cell death1516. The significant increase in progeny survival in animals depleted for bec-1 and atg-7 before 5-FU treatment showed that autophagy, in this case, contributes to toxicity (Fig. 3d).
Figure 3

Activation of autophagy in 5-FU-treated C. elegans.

(a) Autophagy induction in response to 5-FU measured in a GFP::LGG-1 reporter strain fed control RNAi (L4440) or RNAi targeting the indicated genes (scale bars, 10 μm). (b) Immunofluorescence showing anti-VPS-34 staining in dissected embryos in the absence or presence of 5-FU (scale bar, 5 μm). (c) Western blot analysis of embryonic extracts with and without the addition of 5-FU or the autophagy inhibitor 3-MA, detecting the ~40-kDa GFP::LGG-1 fusion protein and the cleaved ~25-kDa product. (d) F1 survival measured after depletion of BEC-1 (red triangles) and ATG-7 (blue squares) as compared with worms fed control RNAi (black diamonds). The survival curve shows the mean±s.d. for each data point from three independent experiments. (e) Induction of autophagy (% GFP-positive embryos) following depletion of the indicated genes. (f) Immunofluorescence showing anti-VPS-34 staining in N2 and atl-1(tm853) embryos in the absence or presence of 5-FU (scale bar, 5 μm). (g) The fraction (as % of untreated control) of embryos with VPS-34-positive foci following 5-FU treatment. (h) Induction of autophagy (% GFP-positive embryos) in control (GFP::LGG-1) and atm-1(gk186) mutants (atm-1; GFP::LGG-1). (e,g,h) Bar graphs represent mean±s.d. from three independent experiments.

A connection was recently described between the ATR (Ataxia telangiectasia and Rad3 related) DNA damage checkpoint and activation of autophagy in yeast19. Depletion of ATL-1 (the C. elegans ATR orthologue20) reduced autophagy induction by about 50% in C. elegans (Fig. 3e and Supplementary Table S4), whereas no effect was seen upon loss of CEP-1 (the C. elegans p53 orthologue; Fig. 3e and Supplementary Table S4). In atl-1(tm853) mutants, there was weaker cytoplasmic anti-VPS-34 staining and the fraction of embryos with VPS-34-positive puncta was halved compared with the N2 control (Fig. 3f,g), supporting a partial requirement of ATL-1 for 5-FU-induced autophagy. In contrast, the fraction of embryos with GFP::LGG-1-positive puncta was indistinguishable in the atm-1(gk186) mutant background and the wild-type background. (Fig. 3h).

DNA repair-dependent induction of autophagy

Next, we asked whether autophagy induction, similar to chromatin decompaction, RPA-1 focus formation, and CHK-1 phosphorylation also depended on DNA repair. This was addressed by counting embryos with GFP::LGG-1-positive foci in animals after RNAi-mediated depletion of individual DNA-repair proteins. All embryos in 5-FU-treated control animals were GFP-positive and depletion of UNG-1 had a minor effect (Fig. 4a,b and Supplementary Table S4). Confirming the survival experiments (Fig. 1c,d), 51% of MSH-2-depleted embryos were GFP positive, whereas depletion of MSH-6, MLH-1, PMS-2, APN-1 and EXO-3 dramatically reduced the number of GFP-positive embryos (Fig. 4b and Supplementary Table S4). Similar results were obtained using accumulation of VPS-34 as a read-out for autophagy activation (Supplementary Fig. S5d,e). Thus, 5-FU-induced autophagy depends on DNA repair. As predicted, as depletion of core autophagy genes attenuated 5-FU toxicity (Fig. 3d), suppression of autophagy further improved survival in the already-tolerant msh-6(pk2504) mutant (Fig. 4c).
Figure 4

DNA repair-dependent induction of autophagy in response to 5-FU.

(a) Induction of autophagy in response to 5-FU in the GFP::LGG-1 reporter strain fed on RNAi targeting the indicated DNA repair genes (scale bars, 10 μm). (b) The fraction (as % of untreated control) of hermaphrodites having embryos with excessive GFP expression following 5-FU treatment. Autophagy induction in independent experiments (circles) and the mean (line) are presented. (c) F1 survival after control (black diamonds) or bec-1 RNAi (red squares) in N2 and msh-6(pk2504) mutants. The survival curve shows the mean±s.d. for each data point from three independent experiments.

We also monitored the expression of the ATF-2 transcription factor, which negatively regulates the expression of autophagy genes such as lgg-1 and bec-1 in C. elegans15. In line with an upstream function of the MutS complex, we found that depletion of msh-2 and msh-6 resulted in 41% and 36% (93 out of 225, or 54 out of 150 embryos scored) of embryos showing excessive ATF-2 expression, which was not seen in the control (1,825 embryos scored; Fig. 5a,b). In contrast, no excessive ATF-2::GFP expression was observed in exo-3 or apn-1-depleted worms (150 embryos scored). Hence, the MutS complex functions to instigate the cellular response cascade leading to DNA-mediated toxicity in response to 5-FU.
Figure 5

Loss of MutS induces ATF-2 expression and attenuates nucleolar stress phenotypes.

(a) Expression of ATF-2::GFP in 5-FU-treated hermaphrodites fed control or RNAi targeting the indicated genes (scale bars, 20 μm). (b) The number of animals harbouring embryos with excessive ATF-2::GFP expression was scored in at least 150 animals and given as the fraction (%) of the total. (c) N2 or msh-6(pk2504) embryos were continuously monitored under differential interference contrast microscopy (scale bars, 5 μm) from the three-cell stage until completion of the four-cell stage. Magnified images of representative nuclei are shown. (d) The fraction of embryos with visible, enlarged nucleoli (arrows) after 5-FU treatment was scored. Bar graphs represent mean±s.d. from three independent experiments.

DNA repair-dependent ribosome biogenesis defect

The DNA repair-dependent accumulation of VPS-34 in the nucleoli indicated that processing of 5-FU-induced DNA damage led to specific problems in this compartment. It is known that 5-FU inhibits ribosome biogenesis at the level of late ribosomal RNA processing21. These phenotypes are commonly interpreted to be resulting from incorporation of 5-fluorouridine triphosphate into RNA2. As regulation of ribosome biogenesis is tightly linked to regulation of chromatin condensation state, we suspected that MMR-dependent chromatin decompaction in response to 5-FU might contribute to these phenotypes. In C. elegans, ribosome biogenesis defects can be monitored as the appearance of visible (enlarged) nucleoli during early embryonic development. The appearance of enlarged nucleoli in ~70% of the four-cell stage embryos treated with 5-FU (Fig. 5c) is therefore a phenotype consistent with an RNA biogenesis defect. The enlarged nucleoli phenotype is in this case, however, unlikely to be a consequence of incorporation of 5-fluorouridine triphosphate into RNA, as it was absent in the msh-6 mutant (Fig. 5c,d). Moreover, the enlarged nucleoli phenotype was not observed after depletion of MSH-2, MLH-1 and EXO-3, and was partially suppressed by APN-1 depletion. In contrast, enlarged nucleoli were seen at wild-type levels after depletion of UNG-1 (Fig. 5d). Hence, the appearance of enlarged nucleoli depended on DNA repair, and its suppression coincided with the suppression of nucleolar VPS-34 staining and failure to induce autophagy. This suggests that RNA- and DNA-mediated 5-FU toxicity have a common mechanistic component.

5-FU induces DNA repair-dependent autophagy in human cells

To confirm the relevance of our finding for human cells, we monitored induction of autophagy in human U2OS cells treated with 10 μM 5-FU. Upon induction of autophagy, cytosolic LC3 (orthologous to C. elegans LGG-1; LC3-I, 18 kDa band) is cleaved and bound to phosphatidylethanolamine in the autophagic membranes (LC3-II, 16 kDa band) and, as LC3-II remains bound to autophagic membranes throughout the pathway, it can be used as a marker for autophagy. A weak but consistent induction of autophagy was seen following 18 h of exposure to 5-FU, with maximum LC3-II expression between 24 and 48 h (Fig. 6a,e). Autophagy was not activated secondarily to apoptosis as neither poly (ADP-ribose) polymerase 1 nor caspase-3 cleavage was observed. Induction of autophagy was suppressed by inhibiting the major mammalian AP endonuclease APE1 by methoxyamine (Mx; Fig. 6a,b). Similarly, a reduction of 5-FU-induced LC3-positive puncta was seen in the presence of Mx in U2OS cells (Fig. 6c,d). Induction of autophagy by 5-FU also depended on MMR in human cells, as depletion of MSH-2 effectively suppressed LC3-II induction (Fig. 6e,f) and formation of LC3-positive puncta (Fig. 6g,h). Similar results were obtained after depletion of MSH-6 by short interfering RNA (siRNA) as expected, as the stability of MSH-2 protein depends on MSH-6 in mammalian cells12 (Supplementary Fig. S6a).
Figure 6

DNA repair-dependent autophagy induction upon 5-FU treatment in human cells.

(a) Western blots showing autophagy induction by monitoring LC3 levels in whole-cell extracts from U2OS cells treated or not with 5-FU alone or in combination with Mx for the indicated time. Staurosporin was used as a positive control for apoptosis induction shown by the appearance of cleaved fragments of caspase-3 (17 and 19 kDa) and poly (ADP-ribose) polymerase 1 (PARP1; ΔPARP, 85 kDa). α−Actin was used as loading control. (b) Quantification of LC3-II levels in cells treated as in a. Intensities of the lower LC3 band (LC3-II) was normalized to those of actin. (c) Autophagy induction demonstrated by accumulation of LC3-positive puncta in U2OS cells treated or not with 5-FU alone or in combination with Mx for 48 h. The cells were fixed and prepared for immunofluorescence of LC3 (green). DAPI staining is shown in blue. Scale bar, 20 μm. (d) Quantification of LC3-positive puncta in cells treated as in c. In each separate experiment, 200–1,600 cells were scored per condition. (e) Western blots showing absence of LC3-II accumulation in U2OS cells transfected with siRNA against MSH-2. The same blot probed with anti-MSH-2 antibodies confirm efficient knockdown. (f) Quantification of LC3-II levels in cells transfected with control or MSH-2 siRNA with or without FU treatment for 24 h. (g) Immunofluorescence showing reduced accumulation of LC3 puncta in U2OS cells transfected with siRNA against MSH-2. (h) Quantification of LC3-positive puncta in cells treated as in g. (i) Quantification of normalized RPS3 protein level (black bars) or RPS3 mRNA level (white bars) in U2OS cells after 48 h 5-FU treatment. RPS3 mRNA levels were determined by quantitative real-time reverse transcriptase–PCR. Graphs (b,d,f,h,i) show mean values±s.e.m. quantified from at least three independent experiments. Student’s t-tests were performed to assess the significance between treatment groups in all panels as indicated; *P<0.05; **P<0.01.

Finally, we asked whether nucleolar proteins or nucleic acids were degraded by autophagy as suggested by the nucleolar VPS-34-positive foci seen in 5-FU-treated C. elegans. Expression of the RPS3 subunit of the 40S small ribosomal particle, which shuttles between the nucleolus and cytoplasm22, was gradually lost in 5-FU-treated U2OS cells (Fig. 6i and Supplementary Fig. S6b), although RPS3 mRNA levels were unaffected (Fig. 6i). Indeed, depletion of Ulk1, a kinase required for induction of autophagy, prevented the 5-FU-induced degradation of RPS3 (Supplementary Fig. S6c,d) confirming that autophagic activity contributed to RPS3 degradation. In summary, we have identified a novel conserved mechanism for 5-FU-induced toxicity. MutS and the BER AP endonucleases are required to elicit DNA-directed toxicity, leading to checkpoint activation and autophagy induction in response to 5-FU in C. elegans embryos and in human cell lines. Epistasis analyses in C. elegans are consistent with MutS and the BER AP endonucleases acting in the same pathway with EXO-3, providing a nick for activation of the MMR pathway in vivo.

Discussion

Preclinical and clinical evidence show that MMR deficiency is associated with poor therapeutic response to a wide range of cytotoxic drugs23. It is not clear whether this effect is due to a classical DNA repair function of MMR or a role for MMR in signalling DNA damage4. The DNA damages induced by 5-FU can be repaired by BER and MMR, but little is known about the nature of the crosstalk between these DNA repair pathways beyond the fact that they share substrates. Here we present genetic and molecular evidence to show that the MMR MutS complex is the upstream requirement for DNA-mediated toxicity. Importantly, we show that the BER AP endonucleases EXO-3 and APN-1 act in the same pathway as classical MMR in eliciting DNA-directed toxicity in response to 5-FU in C. elegans and in a human cell line. We present evidence that EXO-3, the C. elegans orthologue of human APN-1, generates the nicks required for MMR activation in vivo. Processing of 5-FU-induced DNA damage via this pathway led to autophagy activation, which coincided CHK-1 phosphorylation, showing that autophagy is activated as a consequence of DNA damage processing and checkpoint activation. Failure to induce autophagy correlated with resistance to 5-FU. Autophagy was, as such, a determinant for sensitivity. We identified a specific requirement for MMR and BER to elicit 5-FU toxicity. Depletion of genes participating in other DNA repair pathways did not result in similar resistance (Supplementary Fig. S7). Genetic studies in Saccharomyces cerevisiae suggest that the nucleotide excision repair (NER) pathway may contribute to repair of AP sites in the absence of BER24, which might explain the somewhat increased 5-FU sensitivity of a mutant in XPA-1, a DNA damage binding protein required for NER (Supplementary Fig. S7a). In contrast, depletion of ERCC-1 or XPF-1, two proteins that function together as a structure-specific endonuclease in the NER pathway, resulted in a mild tolerance (Supplementary Fig. S7b), but this effect might be due to the role of ERCC-1/XPF-1 in repair of DSB25 rather than in NER. Similar tolerance was also observed after depleting proteins acting in the two main DSB repair pathways, homologous recombination and non-homologous end joining (Supplementary Fig. S7c,d, respectively). These results suggest that both NER and DSB repair pathways may process DNA-repair intermediates generated by MMR and BER in C. elegans, but that they have modest effects on overall toxicity. Moreover, our results revealed that the MutS complex, in particular the MSH-6 protein, acts as the initial sensor of 5-FU-induced DNA damage, as none of the cellular effects induced by 5-FU in the wild-type background was seen in MSH-6-deficient animals; msh-6 mutants showed no chromatin decompaction, failed to activate the DNA damage checkpoint as measured by RPA-1 focus formation and CHK-1 phosphorylation, and failed to induce autophagy. The nature of the in vivo substrates for cytotoxic MMR processing remains to be demonstrated. However, as only BER is expected to be able to process 5-FUra/Ura base paired with adenine, these lesions probably do not contribute much to DNA-mediated toxicity, as lack of UNG-1 does not affect overall survival. Nevertheless, UNG-1-initiated BER probably repairs 5-FU-induced DNA damage, as depletion of exo-3 and apn-1 gave less-effective suppression of toxicity in ung-1 mutants than in the wild type (Supplementary Fig. S2b), and depletion of UNG-1 improved survival in the exo-3 mutant (Supplementary Fig. S2d). Interestingly, the sharp reduction in F1 survival in exo-3-depleted animals treated with higher concentrations of 5-FU (Fig. 1c) was lost in ung-1 mutants (Supplementary Fig. S2b) and, conversely, upon depletion of UNG-1 in exo-3 mutants (Supplementary Fig. S2d). This suggests that BER becomes more important at higher 5-FU concentrations as was previously observed in human cell lines26. BER and MMR both remove 5-FUra/Ura in a mismatched context. Some competition for substrates is supported experimentally with depletion of MSH-2 and MSH-6 being epistatic in ung-1 mutants (Supplementary Fig. S2c). However, MMR is the only pathway expected to be able to detect the mismatched normal bases expected to arise from the nucleotide pool imbalance induced by 5-FU. Hence, MMR might respond to many different substrates in 5-FU-treated cells and it is likely to be that all of these substrates contribute to DNA-mediated toxicity. Importantly, only MMR-initiated processing was associated with checkpoint activation and downstream DNA damage signalling. This is consistent with resistance to 5-FU-based chemotherapy in MMR-defective human cells and tumours4, whereas loss of UNG-1 and SMUG1 DNA glycosylases have little effect25. The requirement of mammalian TDG (thymine–DNA glycosylase) for DNA-mediated toxicity7 might reflect that TDG might compete with MMR for mismatched substrates27. It was recently demonstrated that MMR may act outside of S-phase in response to cytotoxic drugs28. This process, called non-canonical MMR, is uncoupled from replication with the consequence that the DNA ends associated with the replication fork, which direct and activate classical MMR, are not automatically available. It was therefore proposed that non-canonical MMR may hijack nicks generated by BER2829. Non-canonical MMR is associated with extensive gap formation28 and the prominent RPA foci observed here would therefore be compatible with non-canonical MMR. If the activating nicks for non-canonical MMR were intermediates generated by the BER pathway, we would also expect to see a dependency of UNG-1 for RPA filament generation and toxicity. However, no such dependency was observed. Hence, MMR does not hijack nicks generated through ordinary UNG-1-initiated BER. Although, we cannot exclude the possibility that MMR may hijack BER intermediates arising through processing by a cryptic, uncharacterized UDG activity10, the epistasis analyses suggested that the BER AP endonucleases EXO-3 and APN-1 function downstream of MutS. Non-redundant functions for APN-1 and EXO-3, as previously postulated30, were confirmed here, where only depletion of EXO-3 suppressed RPA-1 focus formation. These observations offer in vivo indications that EXO-3 provides nicked intermediates required for recruitment of EXO-1 and thereby activation of the MMR pathway. The in vivo substrates of EXO-3 and APN-1 remain unknown. As neither enzyme is known to incise undamaged DNA, it is likely to be that base damage is involved. As UNG-1-deficiency does not confer resistance, however, this base damage is likely not restricted to UNG-1 substrates. Approximately 77% of APN-1-depleted embryos still displayed prominent RPA-1-positive foci, indicating that the recently described nucleotide incision repair activity of APN-1 (ref. 31) contributes little to this function. RPA-1 focus formation in response to 5-FU depended on MutL, which distinguishes the pathway described here from the alternative mode for repair of oxidative DNA damage in which recruitment of low-fidelity DNA polymerase η depended on MutSα but not on MutLα (ref. 32). Consistently, EXO-1 was the main exonuclease required for RPA-1 focus formation, although the obliteration of RPA-1 focus formation in exo-1 mutants upon APN-1 depletion suggested that the APN-1 3′–5′ exonuclease activity might contribute to DNA resection31. RPA-1 focus formation is used as an early marker of DDR activation. We were therefore interested to note that although RPA-1 foci formed in response to 5-FU in APN-1-depleted cells, they failed to mount a DNA-damage checkpoint response as measured by induction of CHK-1 phosphorylation. Hence, APN-1 functions downstream of RPA-1 filament formation to allow recruitment of the downstream factors required for checkpoint activation. Further experiments are required to pinpoint which activity of the multifaceted APN-1 enzyme is required for checkpoint activation, but the observation that some APN-1-depleted cells had extended RPA-1-positive tracts could point to a possible function of APN-1 in limiting MMR-mediated resection. The observed APN-1-dependent CHK-1 phosphorylation further argues that autophagy was primarily induced as a consequence of DNA damage checkpoint activation resulting from processing the 5-FU-induced DNA damage via the pathway described. As autophagy is a cytoplasmic degradation pathway, it is not obvious how it is activated by DNA damage, but two observations allow us to present a model for autophagy activation in response to 5-FU. First, the appearance of VPS-34 foci in the nucleolus suggested that cargo in this organelle might be collected and targeted for degradation in 5-FU-treated cells. The degradation of RPS3 by autophagy in human cells supported this interpretation. Second, we showed that 5-FU primarily leads to global chromatin decompaction rather than DNA strand breaks. Our data therefore allow us to speculate that a relaxed chromatin landscape induced by MSH-6-initiated processing of 5-FU-induced DNA damage interferes with rDNA organization in the nucleoli leading to autophagy induction. Consistent with this model, the specific degradation of RPS3 by autophagy in human cells indicated that autophagy contributes to remove faulty or excess nucleolar proteins. In summary, the data presented here allow us to propose a model for crosstalk between the BER and MMR pathways in eliciting DDR activation in response to 5-FU where the BER enzyme EXO-3 generates a nick required for MMR activation. Our data suggest that MSH-6-dependent processing of 5-FU-induced DNA damage either within or in the vicinity of the nucleoli is an event leading to toxicity and induction of autophagy. Together, our data strongly suggest that the role of autophagy in mediating DNA damage-induced cell death is more significant than previously anticipated.

Methods

C. elegans strains and culture conditions

C. elegans strains N2 Bristol, msh-2(ok2410) I, mlh-1(ok1917)III and msh-6(pk2504) I were obtained from Caenorhabditis Genetics Center. The ung-1(qa7600) III strain was generated previously11. The exo-3 (tm4374) and exo-1 (tm1842) were obtained from Shohei Mitani (Tokyo Women’s Medical University School of Medicine, Japan). All mutants are expected to be loss-of-function mutants, with the possible exception of the mlh-1(ok1917) mutant, which, if producing a stable protein, would give rise to a truncated protein of 521 aa (Supplementary Fig. S1). The exo.3;msh-6 and exo-3:mlh-1 double mutants were generated for this study. Reporter strains has the following genotypes: buEx070[plgg-1::GFP::LGG-1+rol-6(su1006)] and bec-1(ok691); swEx520[pbec-1::BEC-1::GFP+rol-6(su1006)] and Ex[atf-2::gfp+unc-119(+)]; unc-119(e2497), him-5(e1490)V. adIs2122[lgg-1::GFP+rol-6(su1006)] and atm-1(gk186); adIs2122[lgg-1::GFP+rol-6(su1006)], which were kind gifts from Natascia Ventura (Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany). The atl-1(tm853) IV/nT1[unc-?(n754) let-? qIs50] (IV;V) was a gift from Simon Boulton (Cancer Research UK, London Research Institutes, South Mimms, UK). An Ex[MSH-2::GFP+unc-119(+)]; unc-119(e2497 was generated for this study. Briefly, the msh-2 coding region was amplified using the reverse primer 5′-TTTCCCGGGacaaggctgagaatggcttg-3′ and forward primer 5′-caagccattctcagccttgtAAACCCGGG-3′, and cloned into the pPD95.77 vector into the SmaI and XbaI sites. The construct was cobombarded (with a plasmid containing unc-119(+)) into unc-119(−) mutant animals. The non-Unc progenies were selected and screened for GFP expression. Worms were cultured and maintained at 20 °C using standard procedures, using OP50 as the food source. For experiments using the atl-1(tm853) IV/nT1[unc-?(n754) let-? qIs50] (IV;V) strain, unc and non-unc young adults were exposed to 5-FU, embryos fixed and stained with anti-VPS-34 antibodies. Images of non-unc GFP-negative homozygous atl-1(tm853) mutants are presented. For RNAi experiments, worms were maintained for three generations on Nematode Growth Medium (NGM) plates containing 2 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) seeded with Escherichia coli HT115(DE3) expressing RNAi constructs in the pL4440 feeding vector. The culture condition was 20 °C.

Chemicals and antibodies

5-FU, 5-fluoro-2′-deoxyuridine, methylmethanesulphonate, Mx and 3-MA were from Sigma (Oslo, Norway). The following commercially available antibodies were used: LC3, Ulk1, poly (ADP-ribose) polymerase, Caspase-3 and MSH-6 (Cell Signaling Technology); RPS3 and actin (Abcam); β-actin (Sigma-Aldrich); MSH-2, P-Histone 3(pSer10), P-CHK-1 (pSer345) (Santa Cruz Inc.); anti-Cdk1 (pTyr15) (VWR); and GFP (Roche). Antibodies directed against the following C. elegans proteins were kinds gifts: VPS-34 from Fritz Muller (University of Fribourg); RPA-1 and RAD-51 from Anton Gartner (University of Dundee); and LMN-1 from Yosef Gruenbaum (The Hebrew University of Jerusalem, Israel). RPA-1 from Hyeon Sook Koo (Yonsei University, Seoul, Republic of Korea) and H1X.101 from Monika A Jedrusik (Max Planck Institute for Biophysical Chemistry, Goettingen, Germany). Secondary antibodies were Cy3-conjugated anti-rabbit (Sigma-Aldrich), Alexa 488-conjugated anti-rat and anti-mouse, Alexa Fluor 555-conjugated anti-rabbit and anti-rat (Invitrogen), enhanced chemiluminescence (ECL) anti-rabbit IgG horseradish peroxidase (HRP)-linked whole antibody (GE Healthcare) and anti-mouse IgG HRP-linked (Santa Cruz).

C. elegans toxicity assays

Standard C. elegans toxicity assays were performed after feeding OP50 to N2 or mutant strains on E. coli or after feeding on E. coli HT115(DE3) expressing RNAi. Three stage-4 larvae (L4) were transferred to seeded NGM plates containing 5-FU (0–4 μM) and 2 mM IPTG, and allowed to lay eggs for 28 h. The number of embryos laid was scored after the removal of the hermaphrodite. Survival was scored as the fraction (%) of offspring that developed into adults after 72 h and presented as the mean±s.d. from four independent replicates with at least 150 animals per data point.

C. elegans autophagy

A transgenic reporter strain expressing functional LGG-1 in fusion with GFP (GFP::LGG-1) was used to monitor autophagy induction. Young adults grown on RNAi-expressing food were exposed to 100 μM 5-FU along with RNAi food for 24 h. Worms were anaesthetized with 10 mM levamisol (Sigma) and mounted on 4% agarose pads. Induction of autophagy was monitored under a Zeiss LSM-510 META Confocal microscope with × 63 Plan-Apochromat 1.4 numerical aperture (NA) objective. The number of worms having GFP-positive foci in embryos was scored in 10–60 worms per condition in four independent experiments. To monitor the induction of autophagy in seam cells, L1- to L2-stage larvae were exposed to 100 μM 5-FU for 24 h before scoring the average number of GFP-positive puncta in the seam cells at the L3 stage under a Zeiss Axiovert 200M inverted microscope with × 100 Plan-Apochromat 1.45 NA objective and standard epifluorescence filters. At least four to eight seam cells were observed in each worm in three independent experiments. Expression of the ATF-2 transcription factor in fusion with GFP (ATF-2::GFP) was measured using a transgenic reporter strain in 5-FU-treated hermaphrodites fed control, msh-2, msh-6, or exo-3 RNAi. ATF-2::GFP expression was scored in at least 150 animals per condition.

C. elegans immunofluorescence

For immunohistochemistry, embryos or dissected germlines were collected 24 h after treating synchronized L4 hermaphrodites with 125 Gy ionizing radiation or 100 μM 5-FU. Embryos were placed in 1 × PBS buffer on polylysine-coated slides (Thermo Scientific), covered with coverslips and frozen on dry ice for 20 min. The embryos were fixed in 1:1 acetone:methanol for 10 min at −20 °C, washed in PBS-T (1 × PBS, 0.1% Tween-20) for 5 min, followed by 30 min incubation with image-IT FX signal enhancer (Invitrogen) and 30 min blocking in PBS-TB (1 × PBS, 0.1% Tween-20, 0.5% BSA). The slides were incubated with primary antibody overnight at 4 °C, washed three times 10 min in PBS-T, followed by incubation with the secondary antibody at room temperature for 2 h. Finally, the embryos were washed three times for 10 min in PBS-T and mounted with 7 μl mounting solution containing VECTASHIELD (Vector Lab) and 0.5 μg ml−1 DAPI (Sigma). Germlines were dissected on polylysine-coated slides in egg buffer (25 mM HEPES, pH 7.4, 0.118 M NaCl, 48 mM KCl, 2 mM CaCl2, 2 mM Mg Cl2) supplemented with 0.1% Tween-20 and 0.2 mM levamisol. Germlines were fixed in 4% formaldehyde for 5 min at room temperature and freeze-cracked in liquid nitrogen before further processing, as described above, for embryos. Primary antibodies were used at the following dilutions: RAD-51 (1/200), RPA-1 (1/200), Histone 3 (pSer10) (1/400) and Cdk1 (pTyr15) (1/100). The following secondary antibodies were used for detection: Cy3-conjugated anti-rabbit at 1/10,000 and 1/1,000 for the detection of RAD-51 and Cdk1, respectively, and Alexa 488-conjugated anti-rat at 1/1,000. Primary antibodies were used at the following dilutions; VPS-34 (1:200), RAD-51 (1:100), LMN-1 (1:400) and pCHK1 (1/50). Anti RPA-1 antibodies were used at (1:200) or (1/1,000) (from Drs Gartner and Koo, respectively). The following secondary antibodies were used for detection: Alexa Fluor 555-conjugated anti-rabbit at 1/1,500 for detection of VPS-34, Rad-51, LMN-1 and pCHK1. Alexa Fluor 555 anti-rat at 1/1,500 to detect RPA-1 (Gartner), and Alexa Fluor 488-conjugated anti-mouse at 1/1,000 to detect RPA-1 (Koo). The slides were imaged under a Zeiss LSM-510 METAMK14 Confocal microscope with × 63 Plan-Apochromat 1.4 NA objective.

C. elegans nucleolar stress

Induction of nucleolar stress was monitored as previously described33. Briefly, embryos were dissected out of 5-FU-treated hermaphrodites and observed continuously from the three-cell through the four-cell stage under differential interference contrast in a Zeiss Axiovert 200M inverted microscope with × 100 Plan-Apochromat 1.45 NA objective. A fraction of four-cell stage embryos with visible nucleoli was scored in three independent experiments comprising a minimum of eight embryos per experiment.

C. elegans chromatin decompaction

To examine the chromatin decompaction state after 5-FU treatment, dissected embryos were immunostained with α-LMN-1 as described above to visualize the nuclear membrane. The maximum nuclear diameter was measured in 4-cell embryos in 15–32 embryos per condition after identification of the appropriate focal plane from a z-stack under a Zeiss LSM-510 METAMK14 Confocal microscope with × 63 Plan-Apochromat 1.4 NA objective.

Human cells and transfection

Human osteosarcoma U2OS cells were grown under 5% CO2 in DMEM media supplemented with 10% FCS, 100 U ml−1 penicillin and 100 μg ml−1 streptomycin (all from Gibco). Cells were transfected with siRNA oligos in the absence of antibiotics and serum 1 day after seeding into six-well plates (1.5 × 105 cells per well), using 1 ml transfection solution containing 0.64 μl Lipofectamine RNAiMAX (Invitrogen) and a final concentration of 10 nM siRNA according to the manufacturer’s instructions. After 5 h, the cells received complete growth medium and were cultured for 24 h before addition of the drugs indicated in the figure legends. The siRNA oligos had the following sequences (sense strand): Ulk1-a, 5′-CCACGCAGGUGCAGAACUA-3′ (Dharmacon); Ulk1-b, 5′-UCACUGACCUGCUCCUUAA-3′ (Dharmacon); MSH-2, 5′-CGUCGAUUCCCAGAUCUUA-3′ (GE Healthcare Ambion). Control cells were transfected with a non-targeting control duplex (Dharmacon).

Human cell immunofluorescence

U2OS cells were seeded in Lab-Tek II Chambered Coverglass (Nunc) 1 day before the experiments were performed and treated with 5-FU (10 μM) or Mx (1 mM) for the indicated times. The cells were then fixed in 100% methanol for 10 min and blocked in 5% FCS before incubation with anti-LC3 antibody (Clone 5F10, Nanotools), followed by incubation with Alexa488-labelled donkey anti-mouse antibody (Molecular Probes). The nuclei were stained with DAPI (1 μg ml−1) in PBS. Pictures were taken using a Cell Observer microscope (Zeiss) equipped with a × 40 objective. The number of LC3 spots per cell was quantified from 200 to 1,600 cells per condition in each experiment. Four independent experiments were performed and the mean number of LC3 spots per cell was normalized to that of untreated control cells.

Quantitative real-time reverse transcriptase–PCR

Transcriptional activation of C. elegans ced-13 and egl-1 was measured in synchronized L4 hermaphrodites treated with 100 μM 5-FU for 24 h. For total RNA extraction, worms were disrupted in TRIZOL with 0.7 mm zirconia/silica beads (Biospec Products) using a Mini-Beadbeater 8 (Biospec Products) at maximum speed for 30 s. Complementary DNA synthesis was performed using iScript cDNA synthesis kit from Bio-Rad, according to the manufacturer’s instructions. Quantitative PCR was performed with SYBR Green supermix (Bio-Rad) starting at 95 °C for 30 s, followed by 50 cycles at 95 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s. Transcript levels were normalized to an internal tubulin (tbg-1) control. Primers with the following sequences were used: for egl-1 (5′-CCTCAACCTCTTCGGATCTT-3′) and (5′-TGCTGATCTCAGAGTCATCAA-3′); for ced-13 (5′-GCTCCCTGTTTATCACTTCTC-3′) and (5′-CTGGCATACGTCTTGAATCC-3′); and for tbg-1 (5′-AAGATCTATTGTTCTACCAGGC-3′) and (5′-CTTGAACTTCTTGTCCTTGAC-3′). RNA isolated 24 h after irradiation with ionizing radiation (125 Gy) was included as a positive control. As a control of RNAi efficiency, mRNA expression levels were measured in embryos collected after three generations of feeding N2 animals on E. coli expressing RNAi, targeting the indicated genes. The primers were as follows (sense strand): msh-6 forward: 5′-GATTTGGGAAGTGCTTCGTC-3′, reverse: 5′-TGCAGTCGTTGTGTCAATCA-3′; msh-2 forward: 5′-GAGTGGAGGAAAAGACGAAG-3′, reverse: 5′-CATTTGTTGAGAATTGTCGGTTG-3′; mlh-1 forward: 5′-GAGGAGAAGCTCTTGCATCG-3′, reverse: 5′-GCGGTCATTTTTCCGTCTAA-3′; apn-1 forward: 5′-ACCGGCTATCAGGAAATTGA-3′, reverse: 5′-CCGACTCTTCCTCTTCTTTCA-3′; exo-3 forward: 5′-GGAGGAGACGTTTAAGAACTAC-3′, reverse: 5′-GCTCCGATGAAGGTTCACA-3′; bec-1 forward: 5′-GCGAAACAGTTATCACAGAAGC-3′, reverse: 5′-GAGCGTCAGAGCAATCATTAC-3′; and atg-7 forward: 5′-ATGGCCACGTTTGTTCCC-3′, reverse: 5′-CTTCGGTTTGATGAAGCGAT-3′. For isolation of total RNA from human cells, the RNeasy Plus Mini Kit (QIAGEN) was used according to the manufacturer’s instructions. Total RNA (0.8 μg) was used for cDNA synthesis using the iScript cDNA Synthesis Kit (Bio-Rad). The real-time PCR analysis was run on a CFX96 Real-time PCR Detection System (Bio-Rad) using SsoFast EvaGreen Supermix (Bio-Rad) and prevalidated Quanti-Tect Primer Assays (QIAGEN). The cycling conditions were 95 °C for 1 min, followed by 40 cycles of 95 °C for 5 s, 55 °C for 5 s and 72 °C for 5 s. Relative quantities of Exo-1 or RPS3 transcripts were determined using the regression analysis method provided in the CFX Manager Software (Bio-Rad). Transcript quantities were normalized to the relative quantity of the house-keeping genes TBP (TATA-box binding protein) and SDHA (succinate dehydrogenase complex, subunit A, flavoprotein) for each condition. The following prevalidated Quanti-Tect Primer Assays were used: Hs_RPS3_2_SG, Hs_EXO1_1_SG, Hs_TBP_1_SG and Hs_SDHA_2_SG.

Western blot analyses

Synchronized young GFP::LGG-1-expressing adults were cultured for 24 h on 10 cm OP50-seeded plates with no treatment or in the presence of 100 μM 5-FU. 3-MA (10 mM) was added after 20 h to inhibit autophagy. Embryos were collected by bleaching, washed and resuspended in worm lysis buffer (40 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05%, NP-40, 2 mM EDTA, 1 tablet protease inhibitor from Roche) from N2, msh-6(pk2504), msh-2(ok2410) and MSH-2::GFP. After addition of 1.0 mm zirconia beads (BioSpec product), the embryos were disrupted in a Mini-Beadbeater 8 (BioSpec Products) as described previously33. Protein concentrations were determined using the Bradford Reagent (Bio-Rad) and the extracts were separated on criterion 12.5 and 7.5% precast gels (Bio-Rad), followed by electroblotting to Immobilon-P membranes (Millipore). The blots were probed with primary antibodies (GFP (1:1,000), actin (1:1000) and MSH-6 (1:1,200)) at 4 °C overnight, washed, detected with anti-mouse IgG HRP-linked (Amersham) and anti-rabbit Ig-G HRP (Santa Cruz), and visualized using Supersignal west pico and west femto (Thermo Scientific). For detection of histone 1 × expression, protein extracts were prepared by boiling embryos in nematode solubilizing buffer34 (0.3% ethanolamine, 2 mM EDTA, 1 mM phenylmethylsulphonyl fluoride, 5 mM dithiothreitol and 1 × protease inhibitor) for 25–50 s and immediately added SDS buffer along with reducing agent from the Nu-Page system (Invitrogen). The crude extract was separated in 12% Novex bis tris gel (Invitrogen). The blots were probed with anti H1X.101 (1/1,000)35 and actin (1/1,000) antibodies, detected with ECL anti-rabbit Ig-G HRP (GE Healthcare) antibody at 1/25,000 dilution and visualized using Supersignal west pico and west femto (Thermo Scientific). For preparation of human whole-cell extracts, U2OS cells were washed in cold PBS, lysed in RIPA buffer supplemented with a mixture of protease inhibitors (Roche) and scraped. After a brief sonication, the lysates were cleared and the protein concentrations determined by the BCA Assay (Pierce). Fifteen micrograms of protein per sample was loaded and resolved on 4–20% gradient gels (Bio-Rad) followed by electroblotting to Immobilon-P membranes (Millipore). The blots were probed with specific antibodies, which were detected using standard ECL reagents. The band signal intensities were quantified by the Quantity One software (Bio-Rad) and normalized to those of actin. Full blots can be found in Supplementary Fig. S8.

Statistical analysis

Mean values±s.e.m. were calculated for each condition. The statistical significance of the differences was determined by paired Student’s t-test. *P<0.05; **P<0.01; ***P<0.001 were considered to be statistically significant.

Additional information

How to cite this article: SenGupta, T. et al. Base excision repair AP endonucleases and mismatch repair act together to induce checkpoint-mediated autophagy. Nat. Commun. 4:2674 doi: 10.1038/ncomms3674 (2013).
  34 in total

1.  Steady-state regulation of the human DNA mismatch repair system.

Authors:  D K Chang; L Ricciardiello; A Goel; C L Chang; C R Boland
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

2.  Inactivation of the autophagy gene bec-1 triggers apoptotic cell death in C. elegans.

Authors:  Krisztina Takacs-Vellai; Tibor Vellai; Alessandro Puoti; Myriam Passannante; Chantal Wicky; Adrian Streit; Attila L Kovacs; Fritz Müller
Journal:  Curr Biol       Date:  2005-08-23       Impact factor: 10.834

3.  Identification of two apurinic/apyrimidinic endonucleases from Caenorhabditis elegans by cross-species complementation.

Authors:  Andrea Shatilla; Anick Leduc; Xiaoming Yang; Dindial Ramotar
Journal:  DNA Repair (Amst)       Date:  2005-04-12

4.  The hMsh2-hMsh6 complex acts in concert with monoubiquitinated PCNA and Pol η in response to oxidative DNA damage in human cells.

Authors:  Anastasia Zlatanou; Emmanuelle Despras; Tirzah Braz-Petta; Imenne Boubakour-Azzouz; Caroline Pouvelle; Grant S Stewart; Satoshi Nakajima; Akira Yasui; Alexander A Ishchenko; Patricia L Kannouche
Journal:  Mol Cell       Date:  2011-08-19       Impact factor: 17.970

5.  A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.

Authors:  Zhan Xiao; John Xue; Thomas J Sowin; Saul H Rosenberg; Haiying Zhang
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

6.  Incorporation of dUMP into DNA is a major source of spontaneous DNA damage, while excision of uracil is not required for cytotoxicity of fluoropyrimidines in mouse embryonic fibroblasts.

Authors:  Sonja Andersen; Tina Heine; Ragnhild Sneve; Imbritt König; Hans E Krokan; Bernd Epe; Hilde Nilsen
Journal:  Carcinogenesis       Date:  2004-11-25       Impact factor: 4.944

Review 7.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

Review 8.  Abasic sites in DNA: repair and biological consequences in Saccharomyces cerevisiae.

Authors:  Serge Boiteux; Marie Guillet
Journal:  DNA Repair (Amst)       Date:  2004-01-05

Review 9.  Repair of endogenous DNA damage.

Authors:  T Lindahl; D E Barnes
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2000

10.  A novel linker histone-like protein is associated with cytoplasmic filaments in Caenorhabditis elegans.

Authors:  Monika A Jedrusik; Stefan Vogt; Peter Claus; Ekkehard Schulze
Journal:  J Cell Sci       Date:  2002-07-15       Impact factor: 5.285

View more
  25 in total

1.  The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase.

Authors:  Artur A Serebrenik; Gabriel J Starrett; Sterre Leenen; Matthew C Jarvis; Nadine M Shaban; Daniel J Salamango; Hilde Nilsen; William L Brown; Reuben S Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

2.  C. elegans lifespan extension by osmotic stress requires FUdR, base excision repair, FOXO, and sirtuins.

Authors:  Edward N Anderson; Mark E Corkins; Jia-Cheng Li; Komudi Singh; Sadé Parsons; Tim M Tucey; Altar Sorkaç; Huiyan Huang; Maria Dimitriadi; David A Sinclair; Anne C Hart
Journal:  Mech Ageing Dev       Date:  2016-02-22       Impact factor: 5.432

3.  Hypermutation signature reveals a slippage and realignment model of translesion synthesis by Rev3 polymerase in cisplatin-treated yeast.

Authors:  Romulo Segovia; Yaoqing Shen; Scott A Lujan; Steven J M Jones; Peter C Stirling
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

Review 4.  C. elegans as an Animal Model to Study the Intersection of DNA Repair, Aging and Neurodegeneration.

Authors:  Francisco José Naranjo-Galindo; Ruixue Ai; Evandro Fei Fang; Hilde Loge Nilsen; Tanima SenGupta
Journal:  Front Aging       Date:  2022-06-22

Review 5.  DNA repair, recombination, and damage signaling.

Authors:  Anton Gartner; JoAnne Engebrecht
Journal:  Genetics       Date:  2022-02-04       Impact factor: 4.402

6.  Active transcriptomic and proteomic reprogramming in the C. elegans nucleotide excision repair mutant xpa-1.

Authors:  Henok Kassahun; Hilde Nilsen
Journal:  Worm       Date:  2013-12-05

Review 7.  DNA mismatch repair and the DNA damage response.

Authors:  Zhongdao Li; Alexander H Pearlman; Peggy Hsieh
Journal:  DNA Repair (Amst)       Date:  2015-12-02

8.  BRCA1 and BARD1 mediate apoptotic resistance but not longevity upon mitochondrial stress in Caenorhabditis elegans.

Authors:  Alessandro Torgovnick; Alfonso Schiavi; Anjumara Shaik; Henok Kassahun; Silvia Maglioni; Shane L Rea; Thomas E Johnson; Hans C Reinhardt; Sebastian Honnen; Björn Schumacher; Hilde Nilsen; Natascia Ventura
Journal:  EMBO Rep       Date:  2018-10-26       Impact factor: 8.807

9.  HMCES safeguards replication from oxidative stress and ensures error-free repair.

Authors:  Mrinal Srivastava; Dan Su; Huimin Zhang; Zhen Chen; Mengfan Tang; Litong Nie; Junjie Chen
Journal:  EMBO Rep       Date:  2020-04-19       Impact factor: 8.807

10.  Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

Authors:  Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.